Laurent Pharmaceuticals reaches agreement with US Cystic Fibrosis Foundation to increase Development Award to $US 5M

MONTREAL, QC, Canada – March 14 ^th, 2018

Laurent Pharmaceuticals Inc. (the “Company”), today announced that it has reached an agreement to receive an additional US$ 2 million commitment from US-based Cystic Fibrosis Foundation to further support the upcoming Phase 2 clinical study aimed at demonstrating the safety and efficacy of the Company’s lead compound LAU-7b in adult patients with cystic fibrosis (CF). This new award is in addition to the US$ 3 million development award already committed by the CF Foundation to the Company.

Read more ...

Laurent Pharmaceuticals Receives FDA and Health Canada Clearance to Initiate APPLAUD Phase 2 Clinical Study of LAU-7b for the Treatment of Cystic Fibrosis

MONTREAL, QC, Canada – April 19th, 2017 ^th,

Laurent Pharmaceuticals Inc., a clinical stage orphan drug company, today announced the clearance of its Investigational New Drug

Read more ...

Laurent Pharmaceuticals Receives US$ 3M Development Award From Cystic Fibrosis Foundation Therapeutics

First Canadian Company To Obtain CFFT Therapeutics Development Award 

MONTREAL, QC, Canada – July 26^th, 2016

Laurent Pharmaceuticals Inc. (the “Company”), a clinical stage orphan drug company, today announced it has received a Therapeutics Development Award of up to US$3 million from US-based Cystic Fibrosis Foundation Therapeutics, Inc. (“CFFT”), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation. The award will help support the Phase 2 clinical trial of the Company’s lead drug candidate LAU-7b in adult patients with cystic fibrosis (“CF”).

Read more ...

Laurent Pharmaceuticals featured in Biotech Finances

MONTREAL, QC, Canada – July 18, 2016 ^th, 2015

Laurent Pharmaceuticals featured in Biotech Finances.

Read the article